SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
- PMID: 33436385
- PMCID: PMC8482283
- DOI: 10.1136/annrheumdis-2020-219808
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
Keywords: COVID-19; autoimmune diseases; epidemiology.
Conflict of interest statement
Competing interests: JAS reports research support from Amgen and Bristol-Myers Squibb and consultancy fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, Optum and Pfizer. ZSW reports research support from Bristol-Myers Squibb and Principia and consulting fees from Viela Bio and MedPace. All other authors report no competing interests.
Comment in
-
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C et al.Ann Rheum Dis. 2023 Jun;82(6):e131. doi: 10.1136/annrheumdis-2021-220166. Epub 2021 Mar 10. Ann Rheum Dis. 2023. PMID: 33692020 No abstract available.
-
Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'.Ann Rheum Dis. 2023 Jun;82(6):e130. doi: 10.1136/annrheumdis-2021-220148. Epub 2021 Mar 10. Ann Rheum Dis. 2023. PMID: 33692021 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
